The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

HER2 Signaling

See how Bayer is investigating HER2 signaling across the oncology pipeline

Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.

HER2 Signaling

  • Human epidermal growth factor receptor 2 (HER2) is a protein essential for the regulation of cell proliferation, survival, differentiation, and migration1,2

  • When mutations occur, the altered HER2 protein drives the growth and spread of cancer1,3,4

  • Bayer is investigating a potent and reversible HER2-targeted tyrosine kinase inhibitor (HER2-TKI) aimed at targeting difficult-to-treat, activating HER2 mutations1,3,4

Tumor Types

Lung cancer
Solid tumors

Related Compound

Sevabertinib (BAY 2927088)

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.